Dysregulation of protein kinase activity has been implicated in a number of diseases, including cancer, diabetes, and chronic inflammation. Therefore, protein kinases have emerged as one of the most important drug targets in modern drug discovery. These efforts have resulted in the development of a vast array of small molecule inhibitors that interact with the ATP-binding sites of protein kinases and are able to block their catalytic activities. Interestingly, many of these pharmacological agents exploit the conformational flexibility of the ATP-binding sites of protein kinases by binding to different active site conformations. ATP-competitive inhibitors that stabilize different ATP-binding site conformations of multi-domain protein kinases have been shown to divergently affect domains and interactions outside of their active sites. This proposal will explore how stabilizing different active site conformations of Src-Family Kinases affect their sub-cellular localization, inter-molecular interactions, and signaling behavior. A suite of chemical genetic and chemical proteomic tools is proposed to explore the consequences of conformation-selective, Src-Family Kinase inhibition in diverse cellular contexts.

Public Health Relevance

TFahmisiplyroKjiencatsiessfoincusspeedciofinc cchoanrfaocrtmeraitzioinngshaoffwecstttahbeiilrizbiniogcthheemaicctaivl eansditecseloluf lSarrc- pdst hiirtseoeepdaceeosrventesfi eoliosnrp.mcSmluarectdi-nioFntnagosmfcaainflnfyeecwKcetirtnthahaenesrdeasspicgahenruraeotlinpicnioscgtfeiopnnrrftolciaapamlnetrmchteiearertsaiaonopndfe.SuiEnrtxcifcp-laFtlmoaarrmmgi niealgyttsihKofooni nwr. aasspenseucwmi fibilcleiarncoftofi vrem

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM086858-13
Application #
10089456
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Barski, Oleg
Project Start
2008-09-30
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
13
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Washington
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Golkowski, Martin; Perera, Gayani K; Vidadala, Venkata Narayana et al. (2018) Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. Mol Omics 14:26-36
Hennessey, Kelly M; Rogiers, Ilse C; Shih, Han-Wei et al. (2018) Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum. PLoS Negl Trop Dis 12:e0006673
Lombard, Chloe K; Davis, Audrey L; Inukai, Takayuki et al. (2018) Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors. Biochemistry 57:5897-5909
Rose, John C; Stephany, Jason J; Wei, Cindy T et al. (2018) Rheostatic Control of Cas9-Mediated DNA Double Strand Break (DSB) Generation and Genome Editing. ACS Chem Biol 13:438-442
Rose, John C; Stephany, Jason J; Valente, William J et al. (2017) Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. Nat Methods 14:891-896
Register, Ames C; Chakraborty, Sujata; Maly, Dustin J (2017) Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors. Methods Mol Biol 1636:79-89
Golkowski, Martin; Vidadala, Rama Subba Rao; Lombard, Chloe K et al. (2017) Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors. J Proteome Res 16:1216-1227
Rose, John C; Huang, Po-Ssu; Camp, Nathan D et al. (2017) A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics. Nat Chem Biol 13:119-126
Morita, Shuhei; Villalta, S Armando; Feldman, Hannah C et al. (2017) Targeting ABL-IRE1? Signaling Spares ER-Stressed Pancreatic ? Cells to Reverse Autoimmune Diabetes. Cell Metab 25:883-897.e8
Vidadala, Rama Subba Rao; Rivas, Kasey L; Ojo, Kayode K et al. (2016) Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. J Med Chem 59:6531-46

Showing the most recent 10 out of 51 publications